GLP-1 Market
LLY $1170.14 ▲ +0.5% NVO $39.40 ▼ -1.0% PFE $27.93 ▲ +0.7% VKTX $40.85 ▲ +35.7% KLRA $12.79 ▲ +6.7% GPCR $36.91 ▲ +0.3% RHHBY $55.56 ▲ +0.5%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

ALT001 /kg

ALT001 /kg

Company
Darwin Origin (Hubei) Biopharmaceutical Co., Ltd.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 23, 2026

Trial details
  • Not yet recruiting NCT NCT07833618

    A Phase II Study of ALT001 in Patients With Amyotrophic Lateral Sclerosis (ALS)

    Not yet reported Darwin Origin (Hubei) Biopharmaceutical Co., Ltd. 150 participants Est. completion 2028-12-31 1 site Stand-alone
    Other conditions: Amyotrophic Lateral Sclerosis (ALS)
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: ALT001 /kg, ALT001 1.0 μg/kg, ALT001 2.0 μg/kg

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.